Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

JGCA Risk Classifier (EGC Curability)

The Japanese Gastric Cancer Association (JGCA) / Gotoda criteria classify endoscopic resection (ESD) for Early Gastric Cancer as "Curative", "Expanded Curative", or "Non-Curative".

Evidence-based context for fast calculator use

Purpose:
JGCA criteria classify early gastric cancer endoscopic resection curability to determine if additional surgical gastrectomy is required.
Population:
patients undergoing gastric or pancreatic cancer pathology, recurrence, or postoperative prognostic assessment
Factors:
Invasion Depth, Histology, Ulceration, Tumor Size, Lymphovascular Invasion, Vertical Margins
Reference:
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1-25.
HomeJGCA Risk Classifier (EGC Curability)
Pin your most used calculators here by clicking the star in the dropdown.

JGCA Risk Classifier (EGC Curability)

Clinical Context & Background

The Japanese Gastric Cancer Association (JGCA) / Gotoda criteria classify endoscopic resection (ESD) for Early Gastric Cancer as "Curative", "Expanded Curative", or "Non-Curative". This determines whether additional surgical gastrectomy is required after ESD.
Primary Source EvidenceJapanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1-25.
Formula Logic
Logic based on Size, Ulceration, Histology, Invasion Depth, and Lymphovascular Invasion.

Reference Data

Resection StatusDefinitionAction
eCura A (Absolute)Diff, pT1a, UL-, any size OR Diff, pT1a, UL+, <3cmFollow-up (Curative)
eCura B (Expanded)Diff, pT1b(SM1), <3cm OR Undiff, pT1a, UL-, <2cmFollow-up (Curative)
eCura C-1/C-2Non-curative featuresSurgery Recommended

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use JGCA Risk Classifier (EGC Curability) when jGCA criteria classify early gastric cancer endoscopic resection curability to determine if additional surgical gastrectomy is required.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning eCura A (Absolute) through eCura C-1/C-2.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm resection status, pathologic stage, nodal assessment, margins, histology, treatment timing, and whether the model is postoperative or preoperative.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Postoperative nomograms and fistula-risk tools answer different questions and are not treatment-selection rules.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing gastric or pancreatic cancer pathology, recurrence, or postoperative prognostic assessment

How to apply this result

For a representative case, verify Invasion Depth, Histology, Ulceration, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

MSKCC Pancreatic Cancer NomogramFistula Risk Score (FRS)MSKCC Gastric Cancer Nomogram

Frequently Asked Questions

When should JGCA Risk Classifier (EGC Curability) be used?

Use it for patients undergoing gastric or pancreatic cancer pathology, recurrence, or postoperative prognostic assessment when all required inputs and the intended clinical setting are confirmed.

Can JGCA Risk Classifier (EGC Curability) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.